Source:http://linkedlifedata.com/resource/pubmed/id/12467220
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2002-12-6
|
| pubmed:abstractText |
To date, there is no effective therapy for hormone-independent prostate cancer. Therefore, as a new strategy for refractory cancer, gene therapy is showing increasing promise. In this study, we attempted to use a nonviral gene transfer system, in vivo electroporation, in prostate cancer cell PC-3 xenografts with the wild-type p53 (wt-p53) gene, as gene therapy for hormone-independent prostate cancer. To evaluate this in vivo gene transfer method, the beta-galactosidase gene was transfected into xenografts by electroporation. Then, the efficiency of transfection of exogenous p53 gene by electroporation was confirmed by reverse transcription-PCR, which indicated that p53 mRNA was present in samples from xenografts. Next, to estimate the reduction of prostate cancer xenografts by this method, we measured the size of PC-3 xenografts in nude mice after electroporation with the wt-p53 gene. The growth of tumors was markedly suppressed by wt-p53 gene transfection by electroporation compared with transfection of mutated type p53 gene (P = 0.0027) or vector only (P = 0.0015). Furthermore, histological specimens revealed increased apoptotic cell death in p53-transfected tumors. These results suggest that it is possible to transfer wt-p53 into prostate cancer xenografts using electroporation and to suppress the growth of tumors; they, furthermore, suggest that this system might be used for local advanced hormone-independent prostate cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1535-7163
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
247-52
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12467220-Animals,
pubmed-meshheading:12467220-Apoptosis,
pubmed-meshheading:12467220-DNA Primers,
pubmed-meshheading:12467220-Electroporation,
pubmed-meshheading:12467220-Gene Therapy,
pubmed-meshheading:12467220-Genes, p53,
pubmed-meshheading:12467220-Humans,
pubmed-meshheading:12467220-In Situ Nick-End Labeling,
pubmed-meshheading:12467220-Male,
pubmed-meshheading:12467220-Mice,
pubmed-meshheading:12467220-Mice, Inbred BALB C,
pubmed-meshheading:12467220-Mice, Nude,
pubmed-meshheading:12467220-Point Mutation,
pubmed-meshheading:12467220-Prostatic Neoplasms,
pubmed-meshheading:12467220-RNA, Messenger,
pubmed-meshheading:12467220-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12467220-Transfection,
pubmed-meshheading:12467220-Transplantation, Heterologous,
pubmed-meshheading:12467220-Tumor Cells, Cultured,
pubmed-meshheading:12467220-beta-Galactosidase
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation.
|
| pubmed:affiliation |
Department of Urology, Department of Pathology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|